KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Research & Development (2016 - 2025)

Historic Research & Development for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $58.9 million.

  • CRISPR Therapeutics AG's Research & Development fell 2830.82% to $58.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $283.4 million, marking a year-over-year decrease of 1504.79%. This contributed to the annual value of $320.7 million for FY2024, which is 1721.49% down from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Research & Development stood at $58.9 million for Q3 2025, which was down 2830.82% from $69.9 million recorded in Q2 2025.
  • CRISPR Therapeutics AG's 5-year Research & Development high stood at $123.2 million for Q2 2022, and its period low was $58.9 million during Q3 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's median Research & Development value was $83.5 million (recorded in 2021), while the average stood at $90.0 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Research & Development soared by 18014.18% in 2021, and later crashed by 2830.82% in 2025.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Research & Development stood at $103.1 million in 2021, then grew by 0.45% to $103.6 million in 2022, then fell by 8.12% to $95.1 million in 2023, then fell by 13.65% to $82.2 million in 2024, then fell by 28.3% to $58.9 million in 2025.
  • Its Research & Development stands at $58.9 million for Q3 2025, versus $69.9 million for Q2 2025 and $72.5 million for Q1 2025.